BioAge Labs (NASDAQ:BIOA) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of BioAge Labs (NASDAQ:BIOA) from a sell rating to a strong sell rating in a research report report published on Saturday,Wall Street Zen reports.

A number of other analysts have also recently weighed in on the company. BTIG Research restated a “buy” rating and issued a $40.00 price target on shares of BioAge Labs in a research note on Monday, August 3rd. Jefferies Financial Group set a $21.00 price objective on BioAge Labs in a research report on Friday, July 31st. Roth Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of BioAge Labs in a report on Friday, July 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, July 21st. Finally, Needham & Company LLC decreased their target price on BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $36.57.

BioAge Labs Stock Up 0.9%

NASDAQ BIOA opened at $9.59 on Friday. BioAge Labs has a 52 week low of $4.58 and a 52 week high of $25.95. The firm has a 50 day moving average of $16.50 and a two-hundred day moving average of $17.82. The stock has a market capitalization of $440.18 million, a PE ratio of -4.03 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.07. The business had revenue of $2.45 million for the quarter. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. On average, equities research analysts expect that BioAge Labs will post -2.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioAge Labs

Several large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. acquired a new stake in shares of BioAge Labs during the third quarter worth about $27,000. CWM LLC grew its stake in BioAge Labs by 39.9% during the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after buying an additional 1,053 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in BioAge Labs by 85.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after buying an additional 5,976 shares during the last quarter. Walleye Capital LLC acquired a new position in BioAge Labs during the second quarter worth approximately $64,000. Finally, Bank of America Corp DE increased its position in BioAge Labs by 46.3% during the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after buying an additional 3,517 shares during the period.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.